Comparative Pharmacology
Head-to-head clinical analysis: ERYTHROMYCIN versus ERZOFRI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYTHROMYCIN versus ERZOFRI.
ERYTHROMYCIN vs ERZOFRI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to the 50S ribosomal subunit, inhibiting bacterial protein synthesis by blocking the translocation step.
Erzofri (paliperidone palmitate) is an atypical antipsychotic. Its mechanism of action is not fully understood but is believed to be mediated through a combination of central dopamine type 2 (D2) and serotonin type 2 (5HT2A) receptor antagonism. It also acts as an antagonist at α1 and α2 adrenergic receptors and H1 histaminergic receptors.
250-500 mg orally every 6 hours or 500-1000 mg intravenously every 6 hours; maximum 4 g/day.
Intermittent IV infusion (over 1-2 hours), 100 mg/m² every 2 weeks, or 200 mg/m² every 3 weeks.
None Documented
None Documented
Clinical Note
moderateErythromycin + Norfloxacin
"Erythromycin may increase the QTc-prolonging activities of Norfloxacin."
Clinical Note
moderateErythromycin + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Erythromycin."
Clinical Note
moderateErythromycin + Ibandronate
"Erythromycin may increase the QTc-prolonging activities of Ibandronate."
Clinical Note
moderateErythromycin + Indapamide
Terminal half-life is 1.4-2 hours in adults with normal renal function; may be prolonged to 5-6 hours in anuria.
Terminal elimination half-life approximately 1.5-2 hours. However, due to prolonged inhibition of monoamine oxidase B (MAO-B), clinical effects extend beyond drug presence; enzyme recovery takes several weeks.
Primarily hepatic (biliary) elimination; approximately 2-5% excreted unchanged in urine, 30-60% excreted in feces via bile.
Primarily renal (79% unchanged) and biliary/fecal (15% as metabolites and parent drug); less than 1% in urine as lactam metabolite.
Category A/B
Category C
Macrolide Antibiotic
Macrolide Antibiotic
"Erythromycin may increase the QTc-prolonging activities of Indapamide."